Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

Rhea-AI Summary

Celularity (Nasdaq: CELU) reiterated its strategic commercialization partnership with NEXGEL (Nasdaq: NXGL) to license established biomaterial products and three 510(k) pathway programs. Celularity will be the exclusive manufacturer at its FDA-compliant Florham Park, New Jersey facility.

The transaction is expected to close no later than April 15, 2026, subject to customary closing conditions, and aims to leverage renewed regulatory and reimbursement clarity for placental-derived biomaterials.

Positive

• Exclusive manufacturing agreement at FDA-compliant Florham Park facility
• Established commercial products licensed to NEXGEL (Biovance, Natalin, Interfyl, Acelagraft, Centaflex)
• Three 510(k) pipeline programs (SPARK, FUSE, ORCHID) with potential market impact
• Transaction expected to close by April 15, 2026

Negative

• Transaction subject to customary closing conditions, creating execution risk
• Pipeline programs described as potential disruptors but lack clear regulatory approvals

Key Figures

Expected closing date: April 15, 2026

1 metrics

Expected closing date April 15, 2026 Target date to close NEXGEL commercialization transaction, subject to customary conditions

Market Reality Check

Price: $0.0087 Vol: Volume 5,600 vs 20-day av...

low vol

$0.0087 Last Close

Volume Volume 5,600 vs 20-day average 20,031 (relative volume 0.28) shows limited trading interest ahead of this news. low

Technical Price 0.0087 is trading below the 200-day MA of 0.03 and remains far under the 0.7511 52-week high.

Peers on Argus

CELUW gained 17.57% while key biotech warrants were mixed: BCTXW down 50%, TVGNW...

CELUW gained 17.57% while key biotech warrants were mixed: BCTXW down 50%, TVGNW up 25.46%, others modestly positive or flat. This points to a stock-specific reaction rather than a coordinated sector move.

Previous Partnership Reports

1 past event · Latest: Jul 09 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Jul 09	Strategic partnership	Positive	+38.9%	Partnership with Fountain Life to deliver stem cell therapies in Florida.

Pattern Detected

Partnership announcements have previously coincided with strong positive price moves for Celularity.

Recent Company History

Over the past several months, Celularity has used strategic deals to advance its platform. A prior July 9, 2025 partnership with Fountain Life around stem cell therapies produced a 38.89% one-day gain, highlighting market sensitivity to distribution and commercialization agreements. Against that backdrop, today’s NEXGEL-focused commercialization partnership continues the strategy of leveraging Celularity’s FDA-registered New Jersey facility and placental-derived products through external partners.

Historical Comparison

+38.9% avg move · Past partnership news for CELUW saw an average move of 38.89%. Today’s 17.57% gain reflects a positi...

partnership

+38.9%

Average Historical Move partnership

Past partnership news for CELUW saw an average move of 38.89%. Today’s 17.57% gain reflects a positive but more moderate reaction versus that prior spike.

Partnerships have expanded Celularity’s commercial reach, from Fountain Life’s stem cell access in Florida to NEXGEL’s focus on placental-derived biomaterials and 510(k) pathway devices.

Market Pulse Summary

This announcement reinforces Celularity’s strategy of monetizing placental-derived biomaterials thro...

Analysis

This announcement reinforces Celularity’s strategy of monetizing placental-derived biomaterials through partners, with NEXGEL licensing established products and 510(k) device programs while Celularity remains exclusive manufacturer. Context from a prior Fountain Life partnership, which moved shares 38.89%, shows markets react strongly to commercialization deals. Investors may watch closing progress by April 15, 2026, adoption across wound care and orthopedics, and continued use of Celularity’s FDA-compliant New Jersey facility.

Key Terms

510(k)

1 terms

510(k) regulatory

"Three pipeline 510(k) medical device pathway programs SPARK, FUSE, and ORCHID..."

A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.

AI-generated analysis. Not financial advice.

• Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications.
  
• Three pipeline 510(k) medical device pathway programs SPARK, FUSE, and ORCHID licensed to NEXGEL are potential market disruptors.
  
• Celularity will be the exclusive manufacturer of the licensed products at its FDA-compliant facility in Florham Park, New Jersey, where its vertically integrated manufacturing infrastructure is designed to support scalable, quality-driven production for both commercial-stage products and next-generation placental-derived cellular therapeutics.
  

FLORHAM PARK, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on longevity science, today reiterated that its strategic commercialization partnership with NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL) is a focused effort by the two companies to rapidly capitalize on renewed regulatory and reimbursement clarity around placental-derived biomaterials and build sales and market share. The transaction is expected to close no later than April 15, 2026, subject to customary closing conditions.

“This strategic deal with NEXGEL allows Celularity to focus on a core strength—contract manufacturing—where we have demonstrated over many years our ability to scale and execute cost efficient biomaterial production at a pharmaceutical-like grade,” said Robert J. Hariri, M.D., Ph.D., Chairman and Chief Executive Officer. “NEXGEL is the ideal partner to take these biomaterial products to the next level, with a disciplined, entrepreneurial approach and proven ability to drive value and market growth across industry verticals. Congratulations to the Celularity and NEXGEL teams as we look forward to closing the transaction in April.”

About Celularity

Celularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous cell therapies derived from the postpartum placenta. Celularity leverages the placenta’s unique biology, immunologic properties, and scalable availability to develop therapeutic solutions targeting fundamental mechanisms of aging and age-related disease.

For more information, please visit www.celularity.com.

Forward-Looking Statements

Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the anticipated closing of the strategic commercialization partnership described herein and the expected timing thereof; the potential receipt of upfront consideration, milestone payments, royalties and manufacturing revenues associated with the transaction; the anticipated operational and strategic benefits of the partnership; Celularity’s strategic focus on longevity science, scalable manufacturing infrastructure and capital efficiency; the continued development, regulatory advancement and commercialization of the licensed biomaterials portfolio and development-stage programs; and Celularity’s plans to pursue commercial and clinical opportunities for its technologies in jurisdictions that permit investigational use under applicable law.

Forward-looking statements are based on Celularity’s current expectations and assumptions regarding future events and are subject to risks, uncertainties and changes in circumstances that are difficult to predict. Words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “should,” “will,” and similar expressions are intended to identify forward-looking statements.

Actual results may differ materially from those expressed or implied in forward-looking statements as a result of various risks and uncertainties, including, without limitation, the ability of the parties to satisfy closing conditions and complete the transaction on the anticipated timeline or at all; the ability to realize anticipated financial benefits of the transaction, including milestone payments, royalties or manufacturing revenues; variability in manufacturing volumes or product demand; regulatory developments affecting the development, manufacture or commercialization of Celularity’s products; the successful execution of Celularity’s strategic realignment and organizational restructuring; the development and commercialization of Celularity’s longevity-focused therapeutic programs; and the other risks and uncertainties described under the caption “Risk Factors” in Celularity’s Annual Report on Form 10-K and Form 10-K/A for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on May 8, 2025, and May 21, 2025, respectively, and in Celularity’s other filings with the SEC.

Forward-looking statements speak only as of the date of this press release. Except as required by law, Celularity undertakes no obligation to update or revise any forward-looking statements contained herein to reflect events or circumstances occurring after the date of this press release.

Investor Contact
Carlos Ramirez, Senior Vice President, Celularity Inc.
Carlos.ramirez@celularity.com

FAQ

What did Celularity (CELU) announce about its partnership with NEXGEL on March 12, 2026?

Celularity reiterated a strategic commercialization partnership licensing established biomaterials and 510(k) programs to NEXGEL. According to Celularity, the deal includes exclusive manufacturing at its Florham Park FDA-compliant facility and targets faster commercialization under clarified regulatory and reimbursement conditions.

Which products and programs did Celularity license to NEXGEL in the CELU announcement?

Celularity licensed established products including Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl, and Centaflex. According to Celularity, three pipeline 510(k) programs—SPARK, FUSE, and ORCHID—were also licensed to NEXGEL.

When is the Celularity and NEXGEL transaction expected to close for CELU shareholders?

The companies expect the transaction to close no later than April 15, 2026. According to Celularity, completion remains subject to customary closing conditions and regulatory steps before the listed date.

What manufacturing role will Celularity (CELU) play after the NEXGEL deal?

Celularity will serve as the exclusive manufacturer for the licensed products at its Florham Park facility. According to Celularity, its vertically integrated, FDA-compliant infrastructure will support scalable, quality-driven production for these biomaterials.

How do the licensed 510(k) programs (SPARK, FUSE, ORCHID) affect CELU's business strategy?

The 510(k) programs add potential near-term device opportunities to the licensed portfolio while Celularity focuses on manufacturing. According to Celularity, these programs are positioned as potential market disruptors under NEXGEL's commercialization plan.